Resolution Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
55
- Latest Deal Type
-
Series C
- (Upcoming)
- Investors
-
3
Resolution Therapeutics General Information
Description
Developer of regenerative macrophage cell therapies designed to treat inflammatory organ diseases and support tissue repair. The company offers engineered autologous macrophage therapies that reduce inflammation, limit fibrosis and promote tissue regeneration, enabling patients with advanced organ diseases, including end-stage liver disease, to receive cell-based treatments.
Contact Information
Website
www.resolution-tx.comCorporate Office
- 245 Hammersmith Road
- London W6 8PW
- England, United Kingdom
Corporate Office
- 245 Hammersmith Road
- London W6 8PW
- England, United Kingdom
Resolution Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 31-Jan-2027 | Upcoming | ||||
| 4. Later Stage VC (Series B) | 03-Oct-2024 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A) | 02-Dec-2020 | Completed | Clinical Trials - Phase 2 | |||
| 2. Seed Round | 04-May-2018 | Completed | Clinical Trials - Phase 2 | |||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Resolution Therapeutics Patents
Resolution Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202411901-D0 | Method of producing macrophages | Inactive | 13-Aug-2024 | ||
| GB-202404277-D0 | Method of producing macrophages | Inactive | 26-Mar-2024 | ||
| WO-2025202287-A1 | Method of producing macrophages | Pending | 26-Mar-2024 | ||
| AU-2024352437-A1 | Therapeutic macrophages | Pending | 27-Sep-2023 | ||
| EP-4784730-A1 | Therapeutic macrophages | Pending | 27-Sep-2023 | C12N5/0645 |
Resolution Therapeutics Signals
Resolution Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Old College Capital | Venture Capital | Minority | ||
| Syncona | Venture Capital | Minority | ||
| The University of Edinburgh | University |
Resolution Therapeutics FAQs
-
When was Resolution Therapeutics founded?
Resolution Therapeutics was founded in 2017.
-
Where is Resolution Therapeutics headquartered?
Resolution Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Resolution Therapeutics?
Resolution Therapeutics has 55 total employees.
-
What industry is Resolution Therapeutics in?
Resolution Therapeutics’s primary industry is Drug Discovery.
-
Is Resolution Therapeutics a private or public company?
Resolution Therapeutics is a Private company.
-
What is Resolution Therapeutics’s current revenue?
The current revenue for Resolution Therapeutics is .
-
How much funding has Resolution Therapeutics raised over time?
Resolution Therapeutics has raised $119M.
-
Who are Resolution Therapeutics’s investors?
Old College Capital, Syncona, and The University of Edinburgh have invested in Resolution Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process